This month, the ACR board of directors is on Capitol Hill. As leaders of the organization, they have heard the cry of their membership and are dedicating time to address the concerns of the rheumatology community with Congress.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
The Future of Medicine Is in Washington—You Should Be, Too
On March 10, the ACR hosted its 2009 “Advocates for Arthritis” fly-in. During this event, over 100 rheumatologists, rheumatology health professionals, and patient advocates walked the halls of Congress to lobby legislators on important issues affecting the rheumatology community.
Streamlined Funding Portfolio Increases Efficacy
The ACR Research and Education Foundation recently completed a comprehensive review of its core awards and grants portfolio to assure that it was effective in meeting the needs of junior or early career physician-scientists and health professionals.
Hard Work Behind the Scenes
My first ACR board meeting gives an insider’s view
Reading Rheum
Handpicked Reviews of Contemporary Literature
If Joe the Plumber Gets Arthritis
Campaign figure’s connection to personalized medicine
Sense of Smell
Olfactory defects point to nervous system involvement in lupus
The Arthritis Act: Where Is It Now? What Can I Do?
In September 2008, the “Arthritis Prevention, Control, and Cure Act” passed the House of Representatives. Unfortunately this legislation failed to pass through the Senate and did not become a law. (The Arthritis Act had to be passed in both congressional chambers and signed by the president for the bill to become law.)
Demonstrators Demand More Money for Arthritis Research—What Could Happen?
I recently came across a fictional publication called the Not Yet Gazette with a front-page story dated November 10, 2025, entitled, “Demonstrators demand more money for arthritis research.” The fictional report gave details of a crowd of 100,000, “many in wheelchairs,” confronting the health secretary of that time. The genesis of this fictional article was the observed trend towards the aging of the population and slow growth in research funding. The article stated that, “ ‘Fiscal constraints caused by slow economic growth and resistance to tax increases have greatly reduced allocations for medical research grants in recent years,’ [the health secretary] told the delegates. ‘Unfortunately, in our current political climate, funding for health research is limited,’ she said to reporters after the meeting. ‘We have to devote our limited resources to diseases that are more immediately life-threatening.’ ”
Change on the Mall
Will an election driven by change bring agreeable—and affordable—healthcare reform?
- « Previous Page
- 1
- …
- 286
- 287
- 288
- 289
- 290
- …
- 307
- Next Page »